Replimune

Overview

Replimune Group, Inc. is a clinical-stage biotechnology company headquartered in Woburn, Massachusetts, with substantial operations in Oxfordshire, UK. Established in 2015 by experienced members of the BioVex Inc. team, it specializes in developing next-generation oncolytic immunotherapies using the proprietary Immulytic® platform for cancer treatment.

The organization’s mission is to create therapies that precisely target and destroy cancer cells while stimulating the immune system to produce an anti-tumor response. Notable achievements include advancing leading clinical candidates such as RP1, RP2, and RP3, with a strategic emphasis on combining oncolytic viruses with checkpoint inhibitors to deliver enhanced clinical outcomes.

Basic Information

Contact Details

• Phone: +1 781-222-9600
• Website: replimune.com
• LinkedIn: linkedin.com/company/replimune-inc

Key Focus Areas & Initiatives

• Development of next-generation oncolytic immunotherapies
• Advancement of Immulytic® platform for cancer treatment
• Clinical development of lead candidates (RP1, RP2, RP3)
• Combination therapies with checkpoint inhibitors
• Biotechnology research and innovation
• Health, wellness & fitness initiatives

Technologies Used

• AI
• Adobe Marketing Cloud
• Air
• BASE
• Barracuda Networks
• CAT
• Cloudflare DNS
• Drupal
• ElasticEmail
• Electron
• Elite Software HVAC Solution
• Google Analytics
• Google Tag Manager
• HelpCrunch
• ICP
• Media Temple SSL
• Microsoft Office
• Microsoft Office 365
• Mimecast
• Mobile Friendly
• Ning
• Outlook
• Remote
• Resi
• SAP Crystal Solutions
• Security
• Semrush
• Slack
• Thermo Scientific Chromeleon Chromatography Data System (CDS)
• Vimeo
• WordPress.org
• eMaint CMMS
• iCIMS
• reCAPTCHA

Affiliated Organizations & Regional Branches